Litaker D G, Solomon G D, Genzen J R
Program for Health Economics and Outcomes Research, Cleveland Clinic Foundation 44195, USA.
Headache. 1997 Nov-Dec;37(10):630-4. doi: 10.1046/j.1526-4610.1997.3710630.x.
Quality of life perceptions vary for individuals with similar medical conditions and reflect disease impact. When correlated with subsequent response to treatment, such data may contribute useful insights in understanding the determinants of therapeutic effectiveness in selected medical conditions. Two hundred thirty-five migraine patients never previously treated with injectable sumatriptan completed a Short Form-36 questionnaire before receiving a supervised test dose and a prescription for the medication. Medical records were examined to determine the number of comorbid conditions, headache characteristics (age at onset, headache frequency, duration of disease, aura, association with menses, unilaterality, and emesis), and documentation of sumatriptan's effect in relieving migraine during 12 months of follow-up. Logistic regression was used to identify patient- and disease-specific features most closely associated with the dependent variable, clinical response. One hundred eighty-four patients (78%) reported both relief of symptoms and continued usage of sumatriptan. Patients who experienced emesis with headaches (OR = 2.05 [1.07, 3.91]) and those with higher pretreatment Physical Functioning scores (OR = 3.27 [1.28, 8.37]) were more likely to respond to sumatriptan. Response to sumatriptan therapy was associated with specific pretreatment quality of life domains and headache features. These results may be useful in improving the efficiency of disease management strategies for patients with migraine.
对于患有相似病症的个体而言，生活质量认知存在差异，且反映了疾病的影响。当与后续的治疗反应相关联时，此类数据可能有助于深入了解特定病症中治疗效果的决定因素。235名此前从未接受过注射用舒马曲坦治疗的偏头痛患者，在接受一次监督性试验剂量并获得该药物处方之前，完成了一份简短健康调查问卷（Short Form-36）。查阅医疗记录以确定共病情况的数量、头痛特征（发病年龄、头痛频率、病程、先兆、与月经的关联、单侧性和呕吐情况）以及舒马曲坦在12个月随访期间缓解偏头痛效果的记录。使用逻辑回归来确定与因变量（临床反应）最密切相关的患者和疾病特异性特征。184名患者（78%）报告症状得到缓解且持续使用舒马曲坦。头痛时伴有呕吐的患者（比值比=2.05[1.07, 3.91]）以及治疗前身体功能得分较高的患者（比值比=3.27[1.28, 8.37]）对舒马曲坦治疗更有可能产生反应。舒马曲坦治疗的反应与特定的治疗前生活质量领域和头痛特征相关。这些结果可能有助于提高偏头痛患者疾病管理策略的效率。
